Breakthrough Therapy Designation
Psilocybin Therapy
The active compound in "magic mushrooms," psilocybin is being studied for depression, anxiety, and end-of-life distress. It received FDA Breakthrough Therapy Designation for treatment-resistant depression.
50Clinical Trials
3Companies
6Legal States
FDA StatusBreakthrough Therapy Designation
Legal PathwayState-by-state regulation (OR, CO, NM)
Also Known Asmagic mushrooms, COMP360, psilocin
Legal Status by State
View full legal tracker →Fully Operational
Legal, Launching
Decriminalized
Active Legislation
Research Only
No Activity
Legal & Regulated4
AZCONMOR
Decriminalized2
DCMI
Pending Legislation11
AKCACTGAMANVNJNYTXVTWA
Clinical Trials
Phase 122
Phase 216
Phase 33
Active, Not Recruiting·Phase 1·psilocybin
Psilocybin Brain Stimulation and Imaging Pilot Study
Johns Hopkins University
Healthy Volunteers
Active, Not Recruiting·N/A·psilocybin
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism
Healing Advocacy Fund
Alcohol Use Disorder
Active, Not Recruiting·Phase 2·psilocybin
Psilocybin for Treatment-Resistant Depression
University of Colorado, Denver
Major Depressive DisorderAnhedoniaTreatment Resistant Depression
Active, Not Recruiting·Phase 1·psilocybin
A Study of Psilocybin for PTSD
Johns Hopkins University
Post Traumatic Stress Disorder
Active, Not Recruiting·Phase 2·psilocybin
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
Advanced CancerStage IV Solid Tumor CancerStage IV Sarcoma of Bone+3 more
Active, Not Recruiting·Phase 3·psilocybin
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
Depressive Disorder, Major
Companies & Research
Organizations developing Psilocybin-based therapies